These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 22712112)

  • 1. Symptoms, treatment, and medication reactions for disruptive behavior disorders.
    Finks K
    NASN Sch Nurse; 2012 May; 27(3):125-8. PubMed ID: 22712112
    [No Abstract]   [Full Text] [Related]  

  • 2. Psychotropic prescriptions in a sample including both healthy and mood and disruptive disordered preschoolers: relationships to diagnosis, impairment, prescriber type, and assessment methods.
    Luby JL; Stalets MM; Belden AC
    J Child Adolesc Psychopharmacol; 2007 Apr; 17(2):205-15. PubMed ID: 17489715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design.
    Donovan SJ; Stewart JW; Nunes EV; Quitkin FM; Parides M; Daniel W; Susser E; Klein DF
    Am J Psychiatry; 2000 May; 157(5):818-20. PubMed ID: 10784478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric psychopharmacology: mood, anxiety and disruptive behavior/pervasive developmental disorders.
    McDougle CJ; Krystal JH
    Psychopharmacology (Berl); 2007 Mar; 191(1):1-3. PubMed ID: 17476481
    [No Abstract]   [Full Text] [Related]  

  • 5. Psychopharmacology and preschoolers: a critical review of current conditions.
    Fanton J; Gleason MM
    Child Adolesc Psychiatr Clin N Am; 2009 Jul; 18(3):753-71. PubMed ID: 19486849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of topiramate.
    Kruszewski SP; Klotz SG
    Am J Psychiatry; 2007 Mar; 164(3):526-7; author reply 527-8. PubMed ID: 17329483
    [No Abstract]   [Full Text] [Related]  

  • 7. Amantadine for Treatment of Disruptive Mood Dysregulation Disorder Symptoms.
    Rice T; Simon H; Barckak D; Maiyuran H; Chan V; Hassan Y; Tatum J; Coffey BJ
    J Child Adolesc Psychopharmacol; 2019 Oct; 29(8):642-646. PubMed ID: 31592724
    [No Abstract]   [Full Text] [Related]  

  • 8. Adverse events and the relation with quality of life in adults with intellectual disability and challenging behaviour using psychotropic drugs.
    Scheifes A; Walraven S; Stolker JJ; Nijman HL; Egberts TC; Heerdink ER
    Res Dev Disabil; 2016; 49-50():13-21. PubMed ID: 26647003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulant adherence and academic performance in urban youth with attention-deficit/hyperactivity disorder.
    Marcus SC; Durkin M
    J Am Acad Child Adolesc Psychiatry; 2011 May; 50(5):480-9. PubMed ID: 21515197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of pharmacotherapy of disruptive behavior disorders in children and adolescents.
    Ipser J; Stein DJ
    Psychopharmacology (Berl); 2007 Mar; 191(1):127-40. PubMed ID: 16983542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical characteristics and pharmacotherapy of extremely disruptive behavior disorders in people with mental retardation].
    Tanaka K; Aita C; Hirano M
    No To Hattatsu; 2006 Jan; 38(1):19-24. PubMed ID: 16447792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bad medicine: medicated minors.
    Spence D
    BMJ; 2010 Jul; 341():c3907. PubMed ID: 20659982
    [No Abstract]   [Full Text] [Related]  

  • 13. From the Editor-in-Chief's Desk: Advancing Evidence-Based Treatments for Disruptive Mood Dysregulation Disorder.
    Croarkin PE
    J Child Adolesc Psychopharmacol; 2024 Jun; 34(5):215-216. PubMed ID: 38836845
    [No Abstract]   [Full Text] [Related]  

  • 14. [Impulse control disorders and other serotonin function disorders].
    Pöldinger W
    Praxis (Bern 1994); 1998 Oct; 87(41):1348-55. PubMed ID: 9828665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical Antipsychotic Drugs for Disruptive Behaviour Disorders in Children and Youths.
    Noyce G
    Issues Ment Health Nurs; 2019 Feb; 40(2):185-186. PubMed ID: 30620631
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of sleep medication in children with ADHD.
    Efron D; Lycett K; Sciberras E
    Sleep Med; 2014 Apr; 15(4):472-5. PubMed ID: 24684977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy of disruptive behavior in mentally retarded subjects: A review of the current literature.
    Hässler F; Reis O
    Dev Disabil Res Rev; 2010; 16(3):265-72. PubMed ID: 20981765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities.
    Valicenti-McDermott MR; Demb H
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):549-60. PubMed ID: 17069544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comorbid personality disorder and treatment use in a community sample of youths: a 20-year follow-up.
    Kasen S; Cohen P; Skodol AE; First MB; Johnson JG; Brook JS; Oldham JM
    Acta Psychiatr Scand; 2007 Jan; 115(1):56-65. PubMed ID: 17201867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lithium-induced nephrotic syndrome in a prepubertal boy.
    Petersen CE; Amaral S; Frosch E
    J Child Adolesc Psychopharmacol; 2008 Apr; 18(2):210-3. PubMed ID: 18439118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.